InvestorsHub Logo
Followers 125
Posts 21016
Boards Moderated 0
Alias Born 06/13/2011

Re: None

Friday, 09/13/2019 8:18:00 PM

Friday, September 13, 2019 8:18:00 PM

Post# of 428505
The NLA advisory looks like a pretty narrow "label " to me .
I hope AMRN gets a wider label recommended at Adcom

https://www.lipid.org/nla/nla-position-use-icosapent-ethyl-high-and-very-high-risk-patients

Established ASCVD plus 1 risk factor ...or Diabetic plus 1 risk factor .

It's the additional 1 risk factor that limits this advisory IMHO .

I think it should be all CAD patients on Statins and all Diabetics
JMO

Kiwi
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News